{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T03:40:00Z","timestamp":1752464400937,"version":"3.41.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1023\/a:1005659518030","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T18:07:17Z","timestamp":1040494037000},"page":"587-596","source":"Crossref","is-referenced-by-count":3,"title":["REVIEW: Efficacy of Rabeprazole Once Daily for Acid-Related Disorders"],"prefix":"10.1007","volume":"46","author":[{"given":"Frank","family":"Lanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karna Dev","family":"Bardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Niecestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Barth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"301641_CR1","first-page":"577","volume":"7","author":"JW Freston","year":"1995","unstructured":"Freston JW, Malagelada JR, Petersen H, McCloy RF: Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 7:577\u2013586, 1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"301641_CR2","first-page":"24","volume":"4","author":"KR DeVault","year":"1996","unstructured":"DeVault KR: Current management of gastroesophageal reflux disease. Gastroenterologist 4:24\u201332, 1996","journal-title":"Gastroenterologist"},{"key":"301641_CR3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2036.1997.00181.x","volume":"11","author":"R Lambert","year":"1997","unstructured":"Lambert R: Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:651\u2013662, 1997","journal-title":"Aliment Pharmacol Ther"},{"key":"301641_CR4","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/00007611-199109000-00006","volume":"84","author":"S Holt","year":"1991","unstructured":"Holt S: Proton-pump inhibition for acid-related disease. South Med J 84:1078\u20131087, 1991","journal-title":"South Med J"},{"key":"301641_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/21548331.1996.11443366","volume":"31","author":"DA Johnson","year":"1996","unstructured":"Johnson DA: Medical therapy of GERD: current state of the art. Hosp Pract 31:135\u2013148, 1996","journal-title":"Hosp Pract"},{"key":"301641_CR6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00003495-199549050-00005","volume":"49","author":"EC Klinkenberg-Knol","year":"1995","unstructured":"Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 49:695\u2013710, 1995","journal-title":"Drugs"},{"key":"301641_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0149-2918(96)80175-5","volume":"18","author":"SW Sanders","year":"1996","unstructured":"Sanders SW: Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2\u201334, 1996","journal-title":"Clin Ther"},{"key":"301641_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","volume":"272","author":"NIH Consensus Development Panel.","year":"1994","unstructured":"NIH Consensus Development Panel. Helicobacter pylori in peptic ulcer disease. JAMA 272:65\u201369, 1994","journal-title":"JAMA"},{"key":"301641_CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003495-199855020-00009","volume":"55","author":"A Prakash","year":"1998","unstructured":"Prakash A, Faulds D: Rabeprazole. Drugs 55:261\u2013267, 1998","journal-title":"Drugs"},{"key":"301641_CR10","first-page":"285","volume":"53","author":"JM Mears","year":"1996","unstructured":"Mears JM, Kaplan B: Proton pump inhibitors: new drugs and indications. Am Fam Physician 53:285\u2013292, 1996","journal-title":"Am Fam Physician"},{"key":"301641_CR11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0006-2952(90)90143-9","volume":"29","author":"M Morii","year":"1990","unstructured":"Morii M, Takata H, Fujisaki H, Takeguchi N: The potency of substituted benzimidazoles such as E3810, omeprazole, Ro18-5364 to inhibit gastric H+, K+-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 29:661\u2013667, 1990","journal-title":"Biochem Pharmacol"},{"key":"301641_CR12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-2952(91)90719-L","volume":"42","author":"H Fujisaki","year":"1991","unstructured":"Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N: Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 42:321\u2013328, 1991","journal-title":"Biochem Pharmacol"},{"key":"301641_CR13","doi-asserted-by":"crossref","first-page":"22438","DOI":"10.1074\/jbc.272.36.22438","volume":"272","author":"M Besancon","year":"1997","unstructured":"Besancon M, Simon A, Sachs G, Shin JM: Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thio reagents. J Biol Chem 272:22438\u201322446, 1997","journal-title":"J Biol Chem"},{"key":"301641_CR14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","volume":"12","author":"MP Williams","year":"1998","unstructured":"Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079\u20131089, 1998","journal-title":"Aliment Pharmacol Ther"},{"key":"301641_CR15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0016-5085(88)90162-X","volume":"95","author":"DJ Hetzel","year":"1988","unstructured":"Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903\u2013912, 1988","journal-title":"Gastroenterology"},{"key":"301641_CR16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1023\/A:1018822532736","volume":"43","author":"ML Cloud","year":"1998","unstructured":"Cloud ML, Enas N, Humphries TJ, Bassion S, Rabeprazole Study Group: Rabeprazole in treatment of acid peptic diseases. Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 43:993\u20131000, 1998","journal-title":"Dig Dis Sci"},{"key":"301641_CR17","doi-asserted-by":"crossref","first-page":"A139","DOI":"10.1053\/gast.1996.v110.pm8536850","volume":"110","author":"TJ Humphries","year":"1996","unstructured":"Humphries TJ, Spera A, Breiter J, Farley A, Johnson D, Sabesin S, Wruble L, North American Rabeprazole Study Group: Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 110:A139, 1996 (abstract)","journal-title":"Gastroenterology"},{"key":"301641_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","volume":"13","author":"CPM Dekkers","year":"1999","unstructured":"Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. Aliment Pharmacol Ther 13:49\u201357, 1999","journal-title":"Aliment Pharmacol Ther"},{"key":"301641_CR19","first-page":"1630","volume":"93","author":"C Birbara","year":"1998","unstructured":"Birbara C, Breiter J, Collins D, Jaskir J, Perdomo C, Hahne W: Rabeprazole: preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD. Am J Gastroenterol 93:1630, 1998 (abstract 85)","journal-title":"Am J Gastroenterol"},{"key":"301641_CR20","first-page":"A132","volume":"116","author":"A Caos","year":"1999","unstructured":"Caos A, Moskovitz M, Perdomo C, Niecestro R, Hahne W: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 116:A132, 1999","journal-title":"Gastroenterology"},{"key":"301641_CR21","first-page":"1616","volume":"93","author":"TJ Humphries","year":"1998","unstructured":"Humphries TJ, Dekkers CPM, Beker JA, Thjodleifsson B, Bardhan KD, Jaskir J, Perdomo C, Finnegan V, Bjaaland T, European Rabeprazole Study Group: Rabeprazole vs omeprazole for maintenance therapy of healed erosive GERD: Results of a 1-year multicenter trial. Am J Gastroenterol 93:1616, 1998 (abstract 30)","journal-title":"Am J Gastroenterol"},{"key":"301641_CR22","first-page":"1637","volume":"93","author":"T Humphries","year":"1998","unstructured":"Humphries T, Dekkers C, Beker J, Thjodleifsson B, Rabeprazole GORD Study Group: Magnitude of changes in fasting serum gastrin in 211 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year. Am J Gastroenterol 93:1637, 1998 (abstract 114)","journal-title":"Am J Gastroenterol"},{"key":"301641_CR23","first-page":"A154","volume":"112","author":"TJ Humphries","year":"1997","unstructured":"Humphries TJ, Spera A, Breiter J, Caos A, Farley A, Riff D, Schwartz H, North American Rabeprazole Study Group: Rabeprazole sodium once daily is superior to ranitidine 150 mg bid in the healing of active duodenal ulcer. Gastroenterology 112:A154, 1997 (abstract)","journal-title":"Gastroenterology"},{"key":"301641_CR24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2036.1999.00449.x","volume":"13","author":"CPM Dekkers","year":"1999","unstructured":"Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: A European multicentre study. Aliment Pharmacol Ther 13:179\u2013186, 1999","journal-title":"Aliment Pharmacol Ther"},{"key":"301641_CR25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1365-2036.1998.00373.x","volume":"12","author":"CPM Dekkers","year":"1998","unstructured":"Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ, European Rabeprazole Study Group: Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. Aliment Pharmacol Ther 12:789\u2013795, 1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl1","key":"301641_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000200507","volume":"47","author":"AL Blum","year":"1990","unstructured":"Blum AL: Treatment of acid-related disorders with gastric acid inhibitors: The state of the art. Digestion 47(suppl 1):3\u201310, 1990","journal-title":"Digestion"},{"key":"301641_CR27","first-page":"467","volume":"7","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, L\u00e5ngstr\u00f6m G, Rikner L, Carlsson R, Naesdal J: Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: A meta-analysis. Eur J Gastroenterol Hepatol 7:467\u2013475, 1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"301641_CR28","first-page":"322","volume":"39","author":"L Olbe","year":"1992","unstructured":"Olbe L, Lundell L: Medical treatment of reflux esophagitis. Hepato-Gastroenterol 39:322\u2013324, 1992","journal-title":"Hepato-Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005659518030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005659518030\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005659518030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T03:13:48Z","timestamp":1752462828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005659518030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["301641"],"URL":"https:\/\/doi.org\/10.1023\/a:1005659518030","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}